Novavax, Inc. (NASDAQ:NVAX), announced that it will bring a secondary offering of $100 million in new stock. The stocks took a hit and plunged by more than 7%. The company has announced the pricing of the public offering of 25 million shares of common stock. The underwritten public offering offered will be available to public at $4 per share. It will generate gross proceeds of around $100 million for the company. An amount of approximately $94 million will be deducted as underwriting discount from the net proceeds. The underwriters will have a 30 day option to purchase up to $15 million in additional 3.75 million shares. If it succeeds, the total shares offered will reach 28.75 million shares of its common stock. Novavax, Inc. (NASDAQ:NVAX) weekly performance is -11.46%. On last trading day company shares ended up $4.16. Analysts mean target price for the company is $11.00. Novavax, Inc. (NASDAQ:NVAX), distance from 50-day simple moving average (SMA50) is -3.46%.
On June 04, 2014, MiMedx Group Inc (NASDAQ:MDXG), said Wednesday that the Securities and Exchange Commission has dismissed a lawsuit against the company’s Chairman and CEO Parker “Pete” Petit. MiMedx Group Inc (NASDAQ:MDXG), advanced 2.21% in last trading session and ended the day on $6.00. MDXG, Gross Margin is 84.50% and its return on assets is -5.30%. MiMedx Group Inc (NASDAQ:MDXG), quarterly performance is -17.13%.
On June 05, 2014, The Cooper Companies, Inc. (NYSE:COO), announced financial results for the fiscal second quarter ended April 30, 2014. The Cooper Companies, Inc. (NYSE:COO), shares moved up 1.72% in last trading session and was closed at $133.36, while trading in range of $127.62 – 133.56. The Cooper Companies, Inc. (NYSE:COO), year to date (YTD) performance is 7.71%.
Abaxis Inc (NASDAQ:ABAX), Director Richard Bastiani sold 2,000 shares of the company’s stock on the open market in a transaction dated Thursday, June 5th. The stock was sold at an average price of $42.10, for a total value of $84,200.00. Following the transaction, the director now directly owns 47,400 shares of the company’s stock, valued at approximately $1,995,540. Abaxis Inc (NASDAQ:ABAX), ended the last trading day at $43.54. Company weekly volatility is calculated as 2.26% and price to cash ratio as 9.52. Abaxis Inc (NASDAQ:ABAX), showed a positive weekly performance of 5.37%.
Aerie Pharmaceuticals Inc (NASDAQ:AERI), major shareholder Iv L.P. Acp sold 300,000 shares of Aerie Pharmaceuticals stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $16.00, for a total value of $4,800,000.00. Aerie Pharmaceuticals Inc (NASDAQ:AERI), weekly performance is 5.23%. On last trading day company shares ended up $16.49. Analysts mean target price for the company is $26.25. Aerie Pharmaceuticals Inc (NASDAQ:AERI), distance from 50-day simple moving average (SMA50) is -0.48%.